Novartis aims for four new cancer drugs by 2011

Novartis AG is planning to sell four new cancer treatments by 2011 and expects to rack up $1 billion in annual sales from at least one of those candidates, Novartis Oncology President David Epstein said in an interview. The company is working to launch RAD001, an experimental drug against several types of cancer, followed by ASA404 for non-small-cell lung cancer, SOM230 for a rare group of neuroendocrine tumors and LBH589 for cutaneous T-cell lymphoma.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY